Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy

Background—Primary pulmonary hypertension (PPH) is a severe and progressive disease. Without treatment, the median survival is 2.8 years, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 years, respectively. Intravenous epoprostenol was the first Food and Drug Administration–approved therapy for PPH. The long-term impact that epoprostenol has made on PPH remains to be defined. Methods and Results—One hundred sixty-two consecutive patients diagnosed with PPH and treated with epoprostenol were followed for a mean of 36.3 months (median, 31 months). Data including functional class, exercise tolerance, and hemodynamics were recorded in a customized database. Vital status was verified in each patient. Observed survival with epoprostenol therapy at 1, 2, and 3 years was 87.8%, 76.3%, and 62.8% and was significantly greater than the expected survival of 58.9%, 46.3%, and 35.4% based on historical data. Baseline predictors of survival included exercise tolerance, functional class, right atrial pressure, and vasodilator response to adenosine. Predictors of survival after the first year of therapy included functional class and improvement in exercise tolerance, cardiac index, and mean pulmonary artery pressure. Conclusions—Intravenous epoprostenol improves long-term survival in PPH.

[1]  L. Rubin,et al.  Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.

[2]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[3]  Rian,et al.  A DOSE-DEPENDENT INCREASE IN MORTALITY WITH VESNARINONE AMONG PATIENTS WITH SEVERE HEART FAILURE , 2000 .

[4]  S. Rich,et al.  The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. , 1999, Journal of the American College of Cardiology.

[5]  R. Barst,et al.  Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.

[6]  S. Rich,et al.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.

[7]  L. Rubin,et al.  Primary pulmonary hypertension. , 1988, Lancet.

[8]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[9]  J. Sandoval,et al.  Survival in primary pulmonary hypertension. Validation of a prognostic equation. , 1994, Circulation.

[10]  R. Bain,et al.  Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. , 1993, The New England journal of medicine.

[11]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[12]  E H Bergofsky,et al.  Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .

[13]  W. Gibbons,et al.  Single lung transplantation for primary pulmonary hypertension. , 1990, Chest.

[14]  H. Herrmann,et al.  Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. , 1990, Circulation.

[15]  H. Palevsky,et al.  Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. , 1989, Circulation.

[16]  J. C. Ross,et al.  Primary pulmonary hypertension: a look at the future. , 1989, Journal of the American College of Cardiology.

[17]  H. A. Kahn,et al.  Statistical Methods in Epidemiology , 1989 .

[18]  B. Groves,et al.  The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.

[19]  N. Kanemoto.  Natural history of pulmonary hemodynamics in primary pulmonary hypertension. , 1987, American heart journal.

[20]  E H Bergofsky,et al.  Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.

[21]  E. Robin,et al.  Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation. , 1987, Chest.

[22]  B. Brundage,et al.  Primary pulmonary hypertension: radiographic and scintigraphic patterns of histologic subtypes. , 1986, Annals of internal medicine.

[23]  W. Edwards,et al.  Primary pulmonary hypertension: a histopathologic study of 80 cases. , 1985, Mayo Clinic proceedings.

[24]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[25]  M. Rabinovitch,et al.  A case of spontaneous resolution of idiopathic pulmonary hypertension. , 1981, British heart journal.

[26]  E. Lupi-Herrera,et al.  The role of isoproterenol in pulmonary artery hypertension of unknown etiology (primary): short- and long-term evaluation. , 1981, Chest.

[27]  C. Oakley,et al.  Regression of primary pulmonary hypertension. , 1976, British heart journal.

[28]  E. Trell.  Benign, idiopathic pulmonary hypertension? Two further cases of unusually long duration. , 2009, Acta medica Scandinavica.

[29]  A. Charters,et al.  Primary pulmonary hypertension of unusually long duration. , 1970, British heart journal.

[30]  D. Dresdale,et al.  Primary pulmonary hypertension. I. Clinical and hemodynamic study. , 1951, The American journal of medicine.